by Dr. Joseph Mercola
January 25, 2021
from
Mercola Website
Story at-a-glance
-
While preliminary evidence seems to suggest Ivermectin can be useful
at all stages of SARS-CoV-2 infection, its real strength appears to
be as a preventive approach
-
Of 58 health care workers who took Ivermectin once a month for four
months, only four (6.96%) came down with mild COVID-19 symptoms
during the May through August 2020 trial period, compared to 44 of
60 health care workers (73.3%) who declined the medication
-
In August 2020, India's largest state, Uttar Pradesh, added
Ivermectin to its recommendations and distributed the drug for home
care free of charge. The state of Bihar also started recommending
Ivermectin, and by the end of 2020, Bihar and Uttar Pradesh had the
lowest and second-lowest COVID-19 fatality rates in all of India
-
A WHO-sponsored review suggests Ivermectin can reduce COVID-19
mortality by as much as 83%
-
In the U.S., the Frontline COVID-19 Critical Care Alliance is
calling for widespread adoption of Ivermectin, both as a
prophylactic and for the treatment of all phases of COVID-19
Can
Ivermectin Help Prevent COVID-19 Deaths?
When it comes to the treatment of
COVID-19, many Western nations
have been hobbled by the politicization of medicine.
Throughout 2020, media
and many public health experts warned against the use of
hydroxychloroquine, despite the fact that many practicing doctors
were praising its ability to save patients.
Many of them were
silenced through online censorship. Some even lost their jobs for
the "sin" of publicly sharing their successes with the drug.
Another decades-old antiparasitic drug that offers great hope is
Ivermectin, but it too is being hushed up by mainstream media.
Trial
Site News 1 tells the story of a 77-year-old Indian couple, both of
whom became ill with COVID-19.
One successfully recuperated
following treatment with
hydroxychloroquine.
The other with Ivermectin.
While Ivermectin certainly appears to be a useful strategy, which is
why I am covering it, please understand it is not my primary
recommendation.
If you are looking at this as a
magic bullet, think
again.
You are far better off first
optimizing your vitamin D levels
as I have discussed in dozens of previous articles that you can
easily find in the search engine at the top of the page.
Remember, you need vitamin D for a wide variety of functions in your
body in addition to optimizing your immune response. Although
Ivermectin is a relatively safe drug, it is still an unnatural
synthetic chemical that can have side effects.
Vitamin D is
something your body absolutely requires for optimal health, which is
why I would encourage you to focus on vitamin D first.
Inexpensive
Treatment Responsible for India's Success?
Getting back to Ivermectin, Trial Site News reported 2 that,
"Ten
months into its battle with the SARS-CoV-2 virus, India is on track
to become an unexpected warrior in the fight against this global
pandemic.
Although the densely-populated nation has four times the
population of the U.S., India has less than half the U.S. COVID
deaths."
While India had a daily positive test rate of nearly 100,000 back in
September 2020, by the end of December 2020, the infection rate had
dropped by 75%.
While this rapid decline is by and large being
attributed to strict lockdowns, universal mask wearing and extensive
contact tracing and testing, the availability and use of effective
treatments likely plays a pivotal role.
In late March 2020, India added hydroxychloroquine to its national
treatment guidelines, urging the drug be used,
"as early in the
disease course as possible."
It was not recommended for those
hospitalized with severe illness.
Then, in August 2020, India's largest state, Uttar Pradesh, which
has some 230 million residents, added Ivermectin to its
recommendations and distributed the drug for home care free of
charge.
The state of Bihar, which has 128 million residents, also
started recommending Ivermectin, and by the end of 2020, Bihar and
Uttar Pradesh had the lowest and second-lowest COVID-19 fatality
rates in all of India.
Uttar Pradesh, however, took it a step further than Bihar.
They also
used Ivermectin as a prophylactic, first among health care workers
and then among people who had come in contact with a person who
tested positive.
This drug makes far more sense in India as the vast majority of the
population indeed suffer with parasites as a result of largely
contaminated municipal water supplies.
Frontline Doctors
Call for Adoption of Ivermectin
In the U.S., the Frontline COVID-19 Critical Care Alliance (FLCCC)
is now calling for widespread adoption of Ivermectin, both as a
prophylactic and for the treatment of all phases of COVID-19.
3,4
The data shows
the ability of the drug Ivermectin
to prevent
COVID-19,
to keep those
with early symptoms from progressing to
the
hyper-inflammatory phase of the disease,
and even to help
critically ill patients recover.
FLCCC Alliance
December 8, 2020, FLCCC president Dr. Pierre Kory, former professor
of medicine at St. Luke's Aurora Medical Center in Milwaukee,
Wisconsin, testified before the Senate Committee on Homeland
Security and Governmental Affairs, where he reviewed the evidence
supporting the use of the drug.
(He resigned from St. Luke's shortly
after giving this testimony, saying the medical center wanted to
restrict his freedom of speech.) 5
As noted on the FLCCC
website: 6
"The data shows the ability of the drug Ivermectin to prevent
COVID-19, to keep those with early symptoms from progressing to the
hyper-inflammatory phase of the disease, and even to help critically
ill patients recover.
Dr. Kory testified that Ivermectin is effectively a ‘miracle drug'
against COVID-19 and called upon the government's medical
authorities - the NIH, CDC, and FDA - to urgently review the latest
data and then issue guidelines for physicians, nurse-practitioners,
and physician assistants to prescribe Ivermectin for COVID-19."
January 6, 2020, Kory and Dr.
Paul Marik, chief of pulmonary and
critical care medicine at Eastern Virginia Medical School in
Norfolk, Virginia - both are founding members of FLCCC - also
presented evidence to the National Institutes of Health COVID-19
Treatment Guidelines Panel, which is working to update NIH
guidance. 7
The NIH panel is expected
to update treatment guidelines by early February 2021.
According to the FLCCC:
8
"Numerous clinical studies - including peer-reviewed randomized
controlled trials - showed large magnitude benefits of Ivermectin in
prophylaxis, early treatment and also in late-stage disease.
Taken
together... dozens of clinical trials that have now emerged from
around the world are substantial enough to reliably assess clinical
efficacy.
Data from 18 randomized controlled trials that included over 2,100
patients... demonstrated that Ivermectin produces faster viral
clearance, faster time to hospital discharge, faster time to
clinical recovery, and a 75% reduction in mortality rates."
A one-page summary 9 of the clinical trial evidence for Ivermectin
can be downloaded from the FLCCC website.
A more comprehensive
review 10 of trials data has been published in the journal Frontiers
of Pharmacology.
A listing of all the Ivermectin trials done to
date, with links to the published studies, can be found on
c19Ivermectin.com. 11
How Ivermectin
Protects Against COVID-19
Like hydroxychloroquine, Ivermectin is an antiparasitic drug with a
well-documented safety profile and,
"proven, highly
potent, antiviral and anti-inflammatory properties." 12
It's been on the market
since 1981 and is on the World Health Organization's list of
essential medicines.
It's also inexpensive,
with a treatment course costing less than $2 in countries such as
India and Bangladesh. 13
While the U.S. FDA has not yet approved Ivermectin for prevention of
or treatment for SARS-CoV-2, 14 studies have shown Ivermectin:
15
-
Inhibits
replication of many viruses, including SARS-CoV-2 and
seasonal influenza viruses.
In "COVID-19: Antiparasitic
Offers Treatment Hope," I review data showing a single dose
of Ivermectin killed 99.8% of SARS-CoV-2 in 48 hours
-
Inhibits
inflammation through several pathways
-
Lowers viral load
-
Protects against
organ damage
-
Prevents
transmission of SARS-CoV-2 when taken before or after
exposure; speeds recovery and lowers risk of hospitalization
and death in COVID-19 patients
The FLCCC website also
has a helpful FAQ section 16 where Kory and Marik answer common
questions about the drug and its recommended use.
While FLCCC members have
been criticized for their insistence that we should not wait for
randomized controlled trials before using Ivermectin more widely,
the group argues that the drug has a long history of safety and
clearly works, so, why wait?
"If someone ... says
they want to do an RCT with placebo, that's problematic for me,"
Kory told Medpage Today. 17
"I could not have a
patient admitted to my care and give placebo knowing what I know
about Ivermectin."
One week after Kory and
Marik presented their data, the National Institutes of Health
updated their stand 18 on use of the drug with a statement that they
would not recommend for or against it.
The FLCCC quickly
followed up with their own statement: 19
"By no longer
recommending against Ivermectin use, doctors should feel more
open in prescribing Ivermectin as another therapeutic option for
the treatment of COVID-19.
This may clear its path towards FDA
emergency use approval."
WHO's
Ivermectin Review
While a 75% reduction in mortality is impressive enough (which is
the average reduction based on 18 trials according to the FLCCC)
20,
a WHO-sponsored review 21 suggests Ivermectin can reduce COVID-19
mortality by as much as 83%.
As reported by Swiss
Policy Research: 22
"This result is based
on in-hospital trials, so it does not yet take into account
early ambulatory and prophylactic treatment.
The authors of the
review intend to include three more trials, due to be published
sometime in January, before providing a final conclusion."
In the video above, Dr.
Andrew Hill of the Department of Pharmacology at the
University of Liverpool, U.K., who is leading this review, discusses
the preliminary findings.
At the end, he too
describes Ivermectin as a potentially transformative treatment
against COVID-19.
Ivermectin
Best as Prophylaxis
While preliminary evidence seems to suggest Ivermectin can be useful
at all stages of SARS-CoV-2 infection, its real strength appears to
be prophylactic.
December 26, 2020, Dhaka
Tribune 23 reported the findings of an observational study
24 from
Bangladesh, which looked at Ivermectin as a pre-exposure prophylaxis
for COVID-19 among health care workers.
Fifty-eight volunteers took 12 mg of Ivermectin once per month for
four months.
Only four (6.96%)
came down with mild COVID-19 symptoms during the May through
August 2020 trial period.
In comparison, 44 of
60 health care workers (73.3%) who had declined the medication
were diagnosed with COVID-19.
Both groups worked with
COVID-19 positive patients at the Bangladesh Medical College
Hospital.
Lead researcher Mohammed Tarek Alam told
Dhaka Tribune that Ivermectin is,
"apparently very
effective as a preventive drug."
His team will be seeking permission
to conduct a randomized control trial to validate their findings.
Other
Effective Treatment Options
It's worth noting that while the FLCCC is encouraging the use of
Ivermectin as a prophylactic and early at-home treatment, they also
have a more comprehensive early treatment protocol available, as
well as an in-hospital protocol.
The treatment protocol was initially dubbed MATH+ (an acronym based
on the key components of the treatment), but after several tweaks
and updates, the prophylaxis and early outpatient treatment protocol
is now known as I-MASK+ 25 while the hospital treatment has been
renamed I-MATH+, 26 due to the addition of the drug Ivermectin.
Vitamin C - which has important antioxidant, anti-inflammatory and
immunomodulating effects 27 - is a central component of this
treatment.
As noted in a recent
landmark review 28 on vitamin C for COVID-19, it's common for
hospitalized patients to have overt vitamin C deficiency.
This is
particularly true for older patients and those hospitalized for
respiratory infections...
The two protocols (I-MASK+
29 and I-MATH+ 30) are available for
download on the FLCCC website in multiple languages.
The clinical and
scientific rationale for the I-MATH+ hospital protocol has also been
peer-reviewed and was published in the Journal of Intensive Care
Medicine 31 in mid-December 2020.
Nebulized
Peroxide - My Favorite Treatment Choice
My personal choice for prophylaxis and treatment of COVID-19
symptoms is nebulized peroxide.
This is a home remedy I
recommend everyone familiarize themselves with, as in many cases it
can improve symptoms in mere hours.
Nebulizing hydrogen peroxide into your sinuses, throat and lungs is
a simple, straightforward way to augment your body's natural
expression of hydrogen peroxide to combat infections and can be used
both prophylactically after known exposure to COVID-19 and as,
a
treatment for mild, moderate and even severe illness...
Dr. David Brownstein, who has successfully treated over 100
COVID-19 patients with nebulized peroxide, published a case paper
32
about this treatment in the July 2020 issue of Science, Public
Health Policy and The Law.
He also reviews its
benefits in "How Nebulized Peroxide Helps Against Respiratory
Infections."
Nebulized hydrogen peroxide is extremely safe, and all you need is a
desktop nebulizer and food-grade hydrogen peroxide, which you'll
need to dilute with saline to 0.1% strength.
I recommend buying these
items beforehand so that you have everything you need and can begin
treatment at home at the first signs of a respiratory infection. In
the video above, I go over the basics of this treatment.
The nebulizer I use is the
Pari Trek S Compressor Aerosol System.
The large battery option is unnecessary as you can simply plug in
the device to run it when you need it.
There are likely other
nebulizers you can use instead, as long as it plugs into an
electrical outlet and doesn't use batteries, as they are low-powered
and ineffective nebulizers that don't work as well.
Video
Sources
1, 2
- Trial
Site News January 9, 2021
3, 6
- FLCCC
December 8, 2020
4, 5, 17
- Medpage
Today January 6, 2021
7, 8, 20
- FLCCC
January 7, 2020 Press Release (PDF)
9, 12, 15
- FLCCC
Summary of Clinical Trials Evidence for Ivermectin in
COVID-19 (PDF)
10 - Frontiers
of Pharmacology 2020 DOI: 10.3389/fphar.2021.643369
11 - c19Ivermectin.com
13 - YouTube
Ivermectin Meta-Analysis by Dr. Andrew Hill
14 - U.S.
FDA December 16, 2020
16 - FLCCC
FAQ on Ivermectin
18 - NIH
January 15, 2021
19 - FLCCC
January 15 Press Release
21, 22
- Swiss
Policy Research December 31, 2020
23 - Dhaka
Tribune December 26, 2020
24 - European
Journal of Medical & Health Sciences 2020; 2(6)
25, 29
- FLCCC
Alliance I-MASK+ Protocol
26, 30
- FLCCC
MATH+ Hospital Protocol
27 - Nutrients
December 7, 2020; 12(12): 3760
28 - Nutrients
December 7, 2020; 12(12): 3760, 2. Vitamin C Deficiency in
Pneumonia, Sepsis and COVID-19
31 - Journal
of Intensive Care Medicine December 15, 2020 DOI:
10.1177/0885066620973585
32 - Science,
Public Health Policy and The Law July 2020; 1: 4-22 (PDF)
|